Article
Oncology
Peter H. O'Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher J. Hoimes, Thomas W. Flaig, Nataliya Mar, Helen H. Moon, Terence W. Friedlander, Rana R. McKay, Mehmet A. Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, Jose Pablo Maroto Rey, Christiano Ferrario, Anne-Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg
Summary: EV + Pembro demonstrated a high confirmed objective response rate (cORR) with durable responses as a first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC). Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Bernadett Szabados, Mark Kockx, Zoe June Assaf, Pieter-Jan van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles
Summary: The results of the ABACUS trial showed that neoadjuvant atezolizumab in MIBC is associated with significant clinical responses and high DFS. CD8+ expression and serial ctDNA levels are correlated with outcomes and may contribute to personalized therapy in the future.
Article
Urology & Nephrology
Xiao X. Wei, Lillian Werner, Min Y. Teo, Jonathan E. Rosenberg, Vadim S. Koshkin, Petros Grivas, Bernadett Szabados, Laura Morrison, Thomas Powles, Lucia Carril-Ajuria, Daniel Castellano, Pedro Isaacsson Velho, Noah M. Hahn, Rana R. McKay, Daniele Raggi, Andrea Necchi, Ravindran Kanesvaran, Parissa Alerasool, Jacob Gaines, Matthew Galsky, Joaquim Bellmunt, Guru Sonpavde
Summary: In patients with metastatic urothelial carcinoma, receiving first line PD-1/L1 inhibitors followed by carboplatin containing chemotherapy and the reverse sequence resulted in comparable overall survival.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
G. Galffy, I. Lugowska, E. Poddubskaya, B. C. Cho, M. -J. Ahn, J. -Y. Han, W. -C. Su, R. J. Hauke, S. H. Dyar, D. H. Lee, P. Serwatowski, D. L. Estelles, V. R. Holden, Y. J. Kim, V. Vladimirov, Z. Horvath, A. Ghose, A. Goldman, A. di Pietro, J. Wang, D. A. Murphy, A. Alhadab, M. Laskov
Summary: This study aimed to investigate the clinical outcomes of avelumab plus axitinib in advanced NSCLC or UC patients. The results showed that in NSCLC patients, objective response rate (ORR) was superior to anti-PD-L1 or anti-PD-1 monotherapy, regardless of PD-L1 status. In UC patients, ORR was lower than expected. Rating: 8 out of 10.
Article
Materials Science, Biomaterials
Qiaoying Wang, Changqiang Wu, Xiaoting Li, Dixiao Yang, Liangjun Shi
Summary: The study developed an effective drug delivery system using biocompatible polymer mPEG-PAsp for co-loading chemotherapy drugs PTX and CP, which demonstrated synergistic anti-tumor efficacy. The results suggested that mPEG-PAsp nano-micelles are promising alternatives for carrying and improving the delivery of therapeutic drugs with different water solubilities.
REGENERATIVE BIOMATERIALS
(2021)
Article
Oncology
Matteo Santoni, Zin W. Myint, Thomas Buettner, Hideki Takeshita, Yohei Okada, Elaine T. Lam, Danielle Gilbert, Zsofia Kueronya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, Robert Kemp, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina-Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popovic, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindrich Kopecky, Jakub Kucharz, Annalisa Zeppellini, Ondrej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino M. Monteiro, Nicola Battelli, Fabio Calabro, Camillo Porta
Summary: This study investigated the effectiveness of pembrolizumab as first-line treatment for cisplatin-ineligible UC, and confirmed its role in treating patients who are unfit for cisplatin therapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Alejandra Bernardini, Marta Duenas, Maria Cruz Martin-Soberon, Carolina Rubio, Cristian Suarez-Cabrera, Raquel Ruiz-Palomares, Ester Munera-Maravilla, Sara Lazaro, Iris Lodewijk, Daniel Rueda, David Gomez-Sanchez, Teresa Alonso-Gordoa, Javier Puente, Alvaro Pinto, Pilar Gonzalez-Peramato, Carlos Aguado, Mercedes Herrera, Flora Lopez, Victor M. G. Martinez, Lucia Morales, Daniel Castellano, Jesus M. Paramio, Guillermo de Velasco
Summary: Metastatic urothelial carcinoma is a difficult-to-cure disease with limited treatment options. Vinflunine has shown some improvement in overall survival and is still used for patients who are refractory to chemotherapy and immunotherapy. However, there is a lack of biomarkers to identify responding patients and alternative therapies after treatment failure.
Article
Biochemistry & Molecular Biology
Dai Koguchi, Kazumasa Matsumoto, Masaomi Ikeda, Yuriko Shimizu, Marie Nakamura, Yutaka Shiono, Hiroki Katsumata, Yuichi Sato, Masatsugu Iwamura
Summary: This study retrospectively evaluated the efficacy and tolerability of gemcitabine-paclitaxel as second-line chemotherapy for platinum-based chemotherapy refractory urothelial cancer. It found that gemcitabine-paclitaxel had a moderate objective response rate and overall survival duration, with manageable adverse events. Furthermore, nuclear phosphoglycerate kinase 1 demonstrated predictive value for resistance to platinum-based chemotherapy in urothelial cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Timothy N. Clinton, Ziyu Chen, Hannah Wise, Andrew T. Lenis, Shweta Chavan, Mark T. A. Donoghue, Nima Almassi, Carissa E. Chu, Shawn Dason, Pavitra Rao, James A. Rodrigues, Naresh B. Vasani, Fourat Ridouani, Jonathan E. Rosenberg, Dean F. Bajorin, Min Yuen Teo, Bernard H. Bochner, Michael F. Berger, Irina Ostrovnaya, Eugene J. Pietzak, Gopa Iyer, Sizhi Paul Gao, Wenhuo Hu, Hikmat A. Al-Ahmadie, David B. Solit
Summary: Precision oncology relies on accurate molecular characterization of individual cancer patients at the beginning of treatment. However, tumor molecular profiles are not static and can hinder the application of precision oncology approaches. By analyzing the genomes of primary tumors, metastases, and plasma from patients, we found a high degree of inconsistency in actionable genomic alterations, with certain gene mutations exclusive to metastatic samples. Therefore, circulating tumor DNA profiling may be preferred over tumor sequencing for some patients.
Article
Medicine, General & Internal
M. S. van der Heijden, G. Sonpavde, T. Powles, A. Necchi, M. Burotto, M. Schenker, J. P. Sade, A. Bamias, P. Beuzeboc, J. Bedke, J. Oldenburg, G. Chatta, Y. Urun, D. Ye, Z. He, B. P. Valderrama, J. H. Ku, Y. Tomita, J. Filian, L. Wang, D. Purcea, M. Y. Patel, F. Nasroulah, M. D. Galsky
Summary: In patients with previously untreated advanced urothelial carcinoma, combination therapy with nivolumab plus gemcitabine-cisplatin resulted in significantly better outcomes compared to gemcitabine-cisplatin alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Wataru Fukuokaya, Takafumi Yanagisawa, Masaki Hashimoto, Shutaro Yamamoto, Yuhei Koike, Yu Imai, Kosuke Iwatani, Hajime Onuma, Kagenori Ito, Fumihiko Urabe, Shunsuke Tsuzuki, Shoji Kimura, Jun Miki, Yu Oyama, Hirokazu Abe, Takahiro Kimura
Summary: This study suggests that the effectiveness of pembrolizumab may be retained in ineligible patients with platinum-treated metastatic UC. Expanding trial eligibility criteria for these patients may be beneficial.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Medicine, Research & Experimental
Haitao Wang, Sen Guo, Seung-Jin Kim, Fangyuan Shao, Joshua Wing Kei Ho, Kuan Un Wong, Zhengqiang Miao, Dapeng Hao, Ming Zhao, Jun Xu, Jianming Zeng, Koon Ho Wong, Lijun Di, Ada Hang-Heng Wong, Xiaoling Xu, Chu-Xia Deng
Summary: Cisplatin at different doses has varying effects on breast cancer growth and metastasis, with higher doses inhibiting both growth and metastasis but causing severe side effects, and lower doses only blocking metastasis. Cisplatin prevents breast cancer metastasis by blocking early EMT steps.
Article
Oncology
Evan Y. Yu, Daniel P. Petrylak, Peter H. O'Donnell, Jae-Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. Harrison, Se Hoon Park, David Quinn, Elisabeth Heath, Jonathan E. Rosenberg, Joyce Steinberg, Shang-Ying Liang, Janet Trowbridge, Mary Campbell, Bradley McGregor, Arjun Balar
Summary: Enfortumab vedotin showed promising efficacy in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors, providing a new treatment option for a patient population with a high unmet need.
Article
Multidisciplinary Sciences
Jeffrey S. Damrauer, Wolfgang Beckabir, Jeff Klomp, Mi Zhou, Elizabeth R. Plimack, Matthew D. Galsky, Petros Grivas, Noah M. Hahn, Peter H. O'Donnell, Gopa Iyer, David Quinn, Benjamin G. Vincent, Diane Zipursky Quale, Sara E. Wobker, Katherine A. Hoadley, William Y. Kim, Matthew Milowsky
Summary: UC-GENOME is a genomic analysis study on metastatic urothelial carcinoma, which identified features associated with benefit to chemotherapy and immune checkpoint inhibition, and developed a computational model for predicting immune checkpoint inhibitor response. This study provides a foundation for better understanding the biology of urothelial carcinoma.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Eeeln Buckarma, Cornelius A. Thiels, Zhaohui Jin, Travis E. Grotz
Summary: CRS and HIPEC with paclitaxel and cisplatin is well tolerated and associated with favorable oncologic and perioperative outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2023)